HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylphenidate for fatigue in ambulatory men with prostate cancer.

AbstractBACKGROUND:
Fatigue is a highly prevalent and clinically significant symptom of advanced prostate cancer. To date, however, there are no published controlled trials of interventions for fatigue in men with prostate cancer.
METHODS:
This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients. Inclusion criteria included men with advanced prostate cancer and the presence of moderate to severe fatigue. Patients with major depression, hypothyroidism, uncontrolled hypertension, arrhythmia, or anemia were excluded. Fatigue levels, blood pressure, pulse, and other safety concerns were monitored regularly.
RESULTS:
Thirty-two subjects were randomized to methylphenidate (n=16) or placebo (n=16). Brief Fatigue Inventory total scores significantly decreased for both groups; however, the methylphenidate group, as compared with placebo, reported greater decrease on Brief Fatigue Inventory severity scores (P=.03) and a trend toward greater decrease on Brief Fatigue Inventory total scores (P=.07). A significantly greater number of subjects in the methylphenidate group versus the placebo group demonstrated clinically significant improvement in fatigue on total Brief Fatigue Inventory scores (7 of 10 vs 3 of 13) and Brief Fatigue Inventory severity scores (8 of 10 vs 3 of 13). Importantly, 6 subjects in the methylphenidate group discontinued because of increased blood pressure or tachycardia. There were no serious adverse events.
CONCLUSIONS:
Methylphenidate is effective in treating fatigue in men with prostate cancer; however, oncologists need to monitor for possible pulse and blood pressure elevations.
AuthorsAndrew J Roth, Christian Nelson, Barry Rosenfeld, Howard Scher, Susan Slovin, Michael Morris, Noelle O'Shea, Gabrielle Arauz, William Breitbart
JournalCancer (Cancer) Vol. 116 Issue 21 Pg. 5102-10 (Nov 01 2010) ISSN: 0008-543X [Print] United States
PMID20665492 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 American Cancer Society.
Chemical References
  • Central Nervous System Stimulants
  • Placebos
  • Methylphenidate
Topics
  • Aged
  • Ambulatory Care
  • Blood Pressure (drug effects)
  • Central Nervous System Stimulants (therapeutic use)
  • Double-Blind Method
  • Fatigue (complications, drug therapy)
  • Heart Rate (drug effects)
  • Humans
  • Male
  • Methylphenidate (adverse effects, therapeutic use)
  • Middle Aged
  • Placebos
  • Prostatic Neoplasms (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: